NATHAN FOWLER to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications NATHAN FOWLER has written about Programmed Cell Death 1 Receptor.
Connection Strength
0.251
-
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):356-364.e3.
Score: 0.102
-
Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol. 2015 Sep; 27(5):384-91.
Score: 0.079
-
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77.
Score: 0.070